Terns Pharmaceutical

San Mateo, United States Founded: 2017 • Age: 9 yrs
Therapies for liver disease and cancer are developed.
Request Access

About Terns Pharmaceutical

Terns Pharmaceutical is a company based in San Mateo (United States) founded in 2017.. Terns Pharmaceutical has raised $207.7 million across 3 funding rounds from investors including Lilly, Orbimed and Lilly Asia Ventures. The company has 46 employees as of December 31, 2022. Terns Pharmaceutical offers products and services including Oncology Drugs and Obesity Treatments. Terns Pharmaceutical operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, NGM Biopharmaceuticals and argenx, among others.

  • Headquarter San Mateo, United States
  • Employees 46 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Terns Pharmaceuticals, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $1 M
    0
    as on Dec 31, 2021
  • Net Profit
    $-88.85 M
    2
    as on Dec 31, 2024
  • EBITDA
    $-101.87 M
    1
    as on Dec 31, 2024
  • Total Equity Funding
    $207.7 M (USD)

    in 3 rounds

  • Latest Funding Round
    $97.7 M (USD), Series C

    Jan 05, 2021

  • Investors
    Lilly

    & 7 more

  • Employee Count
    46

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Terns Pharmaceutical

Terns Pharmaceutical is a publicly listed company on the NASDAQ with ticker symbol TERN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: TERN . Sector: Health technology · USA

Products & Services of Terns Pharmaceutical

Terns Pharmaceutical offers a comprehensive portfolio of products and services, including Oncology Drugs and Obesity Treatments. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Small-molecule candidates for treating cancer and related diseases

Products aimed at managing obesity through innovative development

People of Terns Pharmaceutical
Headcount 10-50
Employee Profiles 16
Board Members and Advisors 8
Employee Profiles
People
Joy Zhou
VP, Clinical Development
People
Matt Duan
VP, Pharmaceutical Development
People
Jocel Dumlao
Associate Director
People
Emil Kuriakose
Chief Medical Officer

Unlock access to complete

Board Members and Advisors
people
Carl Gordon
Director
people
Michael Charlton
Scientific Advisor
people
Stephen Harrison
Scientific Advisor
people
Jill M. Quigley
Member Of The Board Of Directors; Audit Chair

Unlock access to complete

Funding Insights of Terns Pharmaceutical

Terns Pharmaceutical has successfully raised a total of $207.7M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $97.7 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series C — $97.7M
  • First Round

    (01 Apr 2018)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2021 Amount Series C - Terns Pharmaceutical Valuation Deerfield
Oct, 2018 Amount Series B - Terns Pharmaceutical Valuation Vivo Capital , Orbimed
Apr, 2018 Amount Series A - Terns Pharmaceutical Valuation Lilly Asia Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Terns Pharmaceutical

Terns Pharmaceutical has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Orbimed and Lilly Asia Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Venture capital and private equity firm
Founded Year Domain Location
Private equity investments are managed across multiple sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Terns Pharmaceutical

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Terns Pharmaceutical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Terns Pharmaceutical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Terns Pharmaceutical

Terns Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, NGM Biopharmaceuticals and argenx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Terns Pharmaceutical

Frequently Asked Questions about Terns Pharmaceutical

When was Terns Pharmaceutical founded?

Terns Pharmaceutical was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Terns Pharmaceutical located?

Terns Pharmaceutical is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.

Is Terns Pharmaceutical a funded company?

Terns Pharmaceutical is a funded company, having raised a total of $207.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Apr 01, 2018.

How many employees does Terns Pharmaceutical have?

As of Dec 31, 2022, the latest employee count at Terns Pharmaceutical is 46.

What is the annual revenue of Terns Pharmaceutical?

Annual revenue of Terns Pharmaceutical is $1M as on Dec 31, 2021.

What does Terns Pharmaceutical do?

Terns Pharmaceuticals was founded in 2017 and is headquartered in San Mateo, United States. Focus is placed on developing treatments for liver conditions including nonalcoholic steatohepatitis and nonalcoholic fatty liver disease, alongside oncology applications. Pipeline candidates encompass TERN-101 as a Farnesoid X Receptor agonist, TERN-201, TERN-501, and a GLP-1R agonist, all targeted at addressing unmet needs in these therapeutic areas. Operations center on advancing clinical-stage assets in the biopharmaceutical sector.

Who are the top competitors of Terns Pharmaceutical?

Terns Pharmaceutical's top competitors include Moderna, argenx and Forge Biologics.

What products or services does Terns Pharmaceutical offer?

Terns Pharmaceutical offers Oncology Drugs and Obesity Treatments.

Is Terns Pharmaceutical publicly traded?

Yes, Terns Pharmaceutical is publicly traded on NASDAQ under the ticker symbol TERN.

Who are Terns Pharmaceutical's investors?

Terns Pharmaceutical has 8 investors. Key investors include Lilly, Orbimed, Lilly Asia Ventures, Vivo Capital, and Suvretta Capital Management.

What is Terns Pharmaceutical's ticker symbol?

The ticker symbol of Terns Pharmaceutical is TERN on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available